Post Stroke Spasticity
Conditions
Brief summary
Determining the mean/median time between botulinum toxin-A injection within the treatment of patients with spasticity after stroke in relation to the botulinum toxin dose from a healthcare insurance database in the Netherlands.
Interventions
None listed
Sponsors
Ipsen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
25 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A patient will be included if he has a diagnosis stroke within the rehabilitation setting and has received at least two injections of botulinum toxin-A: Dysport or Botox
Exclusion criteria
* A patient will be excluded if he has been only treated with Xeomin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean time to next injection per brand | From baseline up to end of data collection (January 2012 up to December 2016) |
| Median time to next injection per brand | From baseline up to end of data collection (January 2012 up to December 2016) |
| Dosing of botulinum toxin-A in daily practice in relation to time to next injection | From baseline up to end of data collection (January 2012 up to December 2016) |
Secondary
| Measure | Time frame |
|---|---|
| Average cost per year per brand per patient | From baseline up to end of data collection (January 2012 up to December 2016) |
| Exploring factors like age, gender, time since diagnosis stroke that influence dosing and time between botulinum toxin-A treatments | From baseline up to end of data collection (January 2012 up to December 2016) |
| Time interval between 2 injections of the same brand | From baseline up to end of data collection (January 2012 up to December 2016) |
Countries
Netherlands
Outcome results
None listed